AtLaS-M 试验:转换为阿扎那韦/利托那韦+拉米夫定双药治疗 48 周后血 HIV-1 DNA 水平的变化
AtLaS-M 随机试验的子研究纳入 201 例病毒学抑制的 HIV-1 感染者,比较转换为阿扎那韦/利托那韦+拉米夫定双药治疗与继续三药治疗 48 周后全血总 HIV-1 DNA 水平的变化。两臂 HIV-1 DNA 均较基线小幅下降,组间差异无统计学意义(-0.009,P=0.842);基线 HIV-1 DNA 较高与第 48 周残留病毒血症相关(P=0.031)。
要点
- 双药与三药治疗 48 周后 HIV-1 DNA 下降幅度相似,支持简化方案对细胞储库的安全性。
- 基线 HIV-1 DNA 较高者第 48 周更易出现残留病毒血症(P=0.031)。
- ART 疗程更长、最低 CD4 更低者 HIV-1 DNA 下降更不明显。
核心结论
- 与继续三药治疗相比,阿扎那韦/利托那韦+拉米夫定双药治疗在持续病毒学抑制患者中使 HIV-1 DNA 水平出现相似下降,支持该简化方案对细胞 HIV-1 储库影响的安全性。
研究设计与样本
- AtLaS-M 随机试验子研究,纳入 266 例随机患者中的 201 例代表性亚组(双药臂 104 例、三药臂 97 例),检测基线与 48 周全血总 HIV-1 DNA 并分析相关因素。
主要发现
- 基线 HIV-1 DNA 均值 2.47 log10 copies/10^6 白细胞,两臂相当。
- 双药臂 48 周较基线平均下降 -0.069 log10 copies/10^6 白细胞(P=0.046),三药臂下降 -0.078(P=0.011)。
- 两臂间平均差异 -0.009(P=0.842)。
- 基线 HIV-1 DNA 与最低 CD4 计数呈负相关(P=0.009);ART 疗程更长、最低 CD4 更低与 HIV-1 DNA 下降幅度更小相关(均 P<0.005)。
- 基线 HIV-1 DNA 较高与第 48 周残留病毒血症相关(P=0.031)。
临床怎么用
- 对持续病毒学抑制的 HIV-1 感染者,可考虑阿扎那韦/利托那韦+拉米夫定双药简化治疗,其对血 HIV-1 DNA 的影响与三药方案相似。
- 基线 HIV-1 DNA 较高者需关注第 48 周残留病毒血症风险。
局限性
- 为 AtLaS-M 试验的代表性亚组分析,仅检测全血总 HIV-1 DNA,未覆盖其他组织储库。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The AtLaS-M randomized trial showed that in patients with HIV-1 RNA <50 copies/mL on atazanavir/ritonavir + two NRTIs, switching to a dual therapy with atazanavir/ritonavir+lamivudine had superior efficacy as compared with continuing the previous triple therapy. This substudy was designed to evaluate at 48 weeks the impact of the dual therapy versus the three-drug atazanavir/ritonavir-based therapy on the HIV-1 cellular reservoir as reflected by the quantification of blood-associated HIV-1 DNA levels. METHODS: In a representative subset of 201 of 266 randomized patients (104 in the dual-therapy arm and 97 in the triple-therapy arm) total HIV-1 DNA levels in whole blood at baseline and after 48 weeks and factors associated with the HIV-1 DNA levels were evaluated. RESULTS: The mean baseline HIV-1 DNA levels (2.47 log 10 copies/10 6 leucocytes) were comparable between arms. A significant mean decrease between baseline and week 48 was observed: -0.069 log 10 copies/10 6 leucocytes in the dual-therapy arm ( P = 0.046) and -0.078 in the triple-therapy arm ( P = 0.011); the mean difference between arms was -0.009 ( P = 0.842). Nadir CD4 count was inversely correlated with baseline HIV-1 DNA ( P = 0.009); longer duration of ART and lower nadir CD4 correlated with a less prominent HIV-1 DNA decrease (both P < 0.005). Higher baseline HIV-1 DNA was associated with residual viraemia at week 48 ( P = 0.031). CONCLUSIONS: When compared with continuing three-drug therapy, atazanavir/ritonavir+lamivudine dual therapy resulted in a similar decline in HIV-1 DNA levels in patients with sustained virological suppression. These data support the safety of this simplified treatment strategy in terms of its effect on the cellular HIV-1 reservoir.
引用
- Lombardi F, Belmonti S, Quiros-Roldan E, et al. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. J Antimicrob Chemother. 2017. PMID: 28333353. doi:10.1093/jac/dkx068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。